Destiny Pharma PLC Grant of share options (0620O)

TIDMDEST

RNS Number : 0620O

Destiny Pharma PLC

08 June 2022

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Brighton, United Kingdom - 8 June 2022 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over 190,000 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following PDMR.

 
 Name               Position          Total number   Total Options held 
                                       of Options      after the grant 
                                      granted under 
                                          award 
                    Chief Medical 
 Dr Yuri Martina     Officer            190,000           190,000 
 

The Options have been granted with an exercise price of GBP0.46 and will vest on 8 June 2025. The Options were granted under award agreements that incorporated the terms of the Plan.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark / Manel Mateus /Vici Rabbetts

[phone]

[e-mail]

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Yuri Martina 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief Medical Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Destiny Pharma plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800O9WH9Z38EHAC95 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the               Grant of award of options over 
       Financial instrument,            ordinary shares of 1 pence each 
       type of instrument               ("Ordinary Shares") under the 
                                        2020 Destiny Pharma plc Long 
                                        Term Incentive Plan. 
      Identification code              DEST GB00BDHSP575 
     -------------------------------  ---------------------------------- 
 b)   Nature of the transaction        Grant of award of options over 
                                        Ordinary Shares under the 2020 
                                        Destiny Pharma plc Long Term 
                                        Incentive Plan. 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)           GBP0.46 pence exercise price 
                                        per Ordinary Share 
                                        190,000 Ordinary Shares 
     -------------------------------  ---------------------------------- 
 d)   Aggregated information: 
       Aggregated volume                 See 4c) above 
       Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          8 June 2022 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange, AIM Market 
     -------------------------------  ---------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFRMFTMTIMBJT

(END) Dow Jones Newswires

June 08, 2022 02:01 ET (06:01 GMT)